Wealthy funder pays reparations for use of HeLa cells
By Alexandra Witze,
Nature
| 10. 29. 2020
Howard Hughes Medical Institute’s six-figure donation is a step towards addressing racial injustice in the sciences.
A major biomedical-research organization has for the first time aimed to make financial reparation for the continuing experimental use of cells from Henrietta Lacks, a Black woman who was the source of the historic ‘HeLa’ cell line, which has been a mainstay of biological research for decades. The Henrietta Lacks Foundation announced the six-figure gift from the Howard Hughes Medical Institute (HHMI) in Chevy Chase, Maryland, on 29 October.
In 1951, doctors took cancerous cells from Lacks without her consent, and later created the HeLa cell line, which today supports a multibillion-dollar biotechnology industry. Lacks died soon after, and for decades, her family saw no financial compensation and were not consulted on other medical decisions stemming from the use of the cells in research.
“We felt it was right to acknowledge Henrietta for the use of HeLa cells and to acknowledge that the cells were gained inappropriately,” says Erin O’Shea, president of the HHMI. “And to acknowledge that we have a long way to go before science and medicine are really equitable.” The HHMI did not disclose the exact amount...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
